カレントテラピー　35-2　サンプル page 11/32

このページは カレントテラピー　35-2　サンプル の電子ブックに掲載されている11ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　35-2　サンプル

14 Current Therapy 2017 Vol.35 No.21127）Waterhouse P, Penninger JM, Timms E, et al：Lymphoproliferativedisorders with early lethality in mice deficient inCTLA-4. Science 270：985-988, 19958）Leach DR, Krummel MF, Allison JP：Enhancement of antitumorimmunity by CTLA -4 blockade. Science 271：1734-1736, 19969）van Elsas A, Hurwitz AA, Allison JP：Combination immunotherapyof B16 melanoma using anti -cytotoxic T lymphocyte-associated antigen 4（CTLA-4）and granulocyte/macrophagecolony -stimulating factor（GM -CSF）-producingvaccines induces rejection of subcutaneous and metastatictumors accompanied by autoimmune depigmentation. J ExpMed 190：355-366, 199910）Ishida Y, Agata Y, Shibahara K, et al：Induced expression ofPD-1, a novel member of the immunoglobulin gene superfamily,upon programmed cell death. EMBO J 11：3887-3895,199211）Freeman GJ, Long AJ, Iwai Y, et al：Engagement of thePD-1 immunoinhibitory receptor by a novel B7 family memberleads to negative regulation of lymphocyte activation. JExp Med 192：1027-1034, 200012）Nishimura H, Nose M, Hiai H, et al：Development of lupuslikeautoimmune diseases by disruption of the PD-1 geneencoding an ITIM motif-carrying immunoreceptor. Immunity11：141-151, 199913）Nishimura H, Okazaki T, Tanaka Y, et al：Autoimmunedilated cardiomyopathy in PD-1 receptor-deficient mice. Science291：319-322, 200114）Latchman Y, Wood CR, Chernova T, et al：PD-L2 is a secondligand for PD-1 and inhibits T cell activation. Nat Immunol2：261-268, 200115）Iwai Y, Terawaki S, Ikegawa M, et al：PD-1 inhibits antiviralimmunity at the effector phase in the liver. J Exp Med198：39-50, 200316）Iwai Y, Ishida M, Tanaka Y, et al：Involvement of PD-L1 ontumor cells in the escape from host immune system andtumor immunotherapy by PD-L1 blockade. Proc Natl AcadSci USA 99：12293-12297, 200217）Iwai Y, Terawaki S, Honjo T：PD-1 blockade inhibits hematogenousspread of poorly immunogenic tumor cells byenhanced recruitment of effector T cells. Int Immunol 17：133-144, 200518）Phan GQ, Yang JC, Sherry RM, et al：Cancer regression andautoimmunity induced by cytotoxic T lymphocyte-associatedantigen 4 blockade in patients with metastatic melanoma.Proc Natl Acad Sci USA 100：8372-8377, 200319）Hodi FS, O’Day SJ, McDermott DF, et al：Improved survivalwith ipilimumab in patients with metastatic melanoma. NEngl J Med 363：711-723, 201020）Topalian SL, Hodi FS, Brahmer JR, et al：Safety, activity,and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 366：2443-2454, 2012